PAVmed (PAVM) Equity Ratio (2015 - 2025)
PAVmed's quarterly Equity Ratio came in at 0.57 in Q4 2025, up 806.06% year-on-year from 0.06 in Q4 2024, and down 32.74% quarter-over-quarter from 0.85 in Q3 2025.
PAVmed has reported Equity Ratio for 11 years, with the latest figure at 0.57 in Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio rose 806.06% year-over-year to 0.57; the trailing twelve-month figure through Dec 2025 stood at 0.57 (up 806.06% YoY), and the FY2025 full-year result was 0.57, up 806.06% from the prior year.
- Equity Ratio for Q4 2025 stood at 0.57, down from 0.85 in the prior quarter.
- The five-year high for Equity Ratio was 0.94 in Q1 2021, with the low at 0.73 in Q4 2023.
- Average Equity Ratio over 5 years is 0.33, with a median of 0.45 recorded in 2022.
- Year-over-year, Equity Ratio jumped 3918.04% in 2021 and slumped 2959.23% in 2024.
- Tracing PAVM's Equity Ratio over 5 years: stood at 0.91 in 2021, then tumbled by 77.82% to 0.2 in 2022, then sank by 458.03% to 0.73 in 2023, then surged by 88.78% to 0.08 in 2024, then jumped by 806.06% to 0.57 in 2025.
- The last three Equity Ratio figures came in at 0.57 (Q4 2025), 0.85 (Q3 2025), and 0.64 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.47 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.50 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.54 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.59 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.78 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 0.45 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.29 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.67 |
| 10 | PAVmed | 4.15 Mn | -9.02 Mn | -703,000.00 | 0.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.57 |
| Sep 30, 2025 | 0.85 |
| Jun 30, 2025 | 0.64 |
| Mar 31, 2025 | 0.74 |
| Dec 31, 2024 | -0.08 |
| Sep 10, 2024 | 0.37 |
| Jun 30, 2024 | -0.47 |
| Mar 31, 2024 | -0.55 |
| Dec 31, 2023 | -0.73 |
| Sep 30, 2023 | -0.38 |
| Jun 30, 2023 | -0.02 |
| Mar 31, 2023 | 0.17 |
| Dec 31, 2022 | 0.20 |
| Sep 30, 2022 | 0.39 |
| Jun 30, 2022 | 0.50 |
| Mar 31, 2022 | 0.77 |
| Dec 31, 2021 | 0.91 |
| Sep 30, 2021 | 0.82 |
| Jun 30, 2021 | 0.89 |
| Mar 31, 2021 | 0.94 |
| Dec 31, 2020 | -0.02 |
| Sep 30, 2020 | -1.41 |
| Jun 30, 2020 | -1.44 |
| Mar 31, 2020 | -1.60 |
| Dec 31, 2019 | -0.64 |
| Sep 30, 2019 | -0.55 |
| Jun 30, 2019 | -0.27 |
| Mar 31, 2019 | -1.30 |
| Dec 31, 2018 | -0.29 |
| Sep 30, 2018 | 0.38 |
| Jun 30, 2018 | 0.58 |
| Mar 31, 2018 | 0.07 |
| Dec 31, 2017 | -1.74 |
| Sep 30, 2017 | -1.83 |
| Jun 30, 2017 | -22.30 |
| Mar 31, 2017 | -3.94 |
| Dec 31, 2016 | -0.37 |
| Sep 30, 2016 | 0.58 |
| Jun 30, 2016 | 0.87 |
| Dec 31, 2015 | 0.52 |